Cellebrite DI Ltd. (NASDAQ:CLBT) finished Friday with an addition of $0.3 to close at $7.70, an upside of 4.05 percent. An average of 585,980 shares of common stock have been traded in the last five days. There was a gain of $0.31 in the past week, and it reached a new high 24 times over the past 12 months. The last 20 days have seen an average of 395,840 shares traded, while the 50-day average volume stands at 324,814.
CLBT stock has increased by 7.54% in the last month. The company shares reached their 1-month lowest point of $6.73 on 07/12/23. With the stock rallying to its 52-week high on 08/09/23, shares of the company touched a low of $3.80 and a high of $8.15 in 52 weeks. It has reached a new high 27 times so far this year and achieved 76.61% or $3.34 in price. In spite of this, the price is down -5.52% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Cellebrite DI Ltd. (CLBT) has a trailing price-to-earnings (P/E) ratio of 79.38. The stock’s beta is 1.32. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.36, the price-to-book (PB) ratio at 36.67, and the price-to-cash flow ratio at 41.88.
Financial Health
The quick ratio of Cellebrite DI Ltd. for the three months ended June 29 was 1.50, and the current ratio was 1.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Cellebrite DI Ltd.’s EBITDA margin for the year ending June 29 is 4.51%, while its operating margin for the same period stands at 1.10%. Its gross profit as reported stood at $219.91 million compared to revenue of $270.65 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cellebrite DI Ltd.’s return on assets was 5.40%.
Earnings Surprise
For the three-month period that ended June 29, Cellebrite DI Ltd. had $44.64 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $116.11 million in the quarter, while revenues were grew 39.34%. The analyst consensus anticipated Cellebrite DI Ltd.’s latest quarter earnings to come in at $0.02 per share, but it turned out to be $0.05, a 150.00% surprise. For the quarter, EBITDA amounted to $6.9 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Cellebrite DI Ltd. (CLBT) price momentum. RSI 9-day as of the close on 11 August was 54.74%, suggesting the stock is Neutral, with historical volatility in this time frame at 71.35%.
As of today, CLBT’s price is $7.70 +4.19% or $0.31 from its 5-day moving average. CLBT is currently trading +10.32% higher than its 20-day SMA and +35.09% higher than its 100-day SMA. However, the stock’s current price level is +33.45% above the SMA50 and +61.43% above the SMA200.
The stochastic %K and %D were 55.56% and 64.68%, respectively, and the average true range (ATR) was 0.35. With the 14-day stochastic at 55.88% and the average true range at 0.32, the RSI (14) stands at 56.31%. The stock has reached 0.10 on the 9-day MACD Oscillator while the 14-day reading was at 0.09.
Analyst Ratings
Craig Hallum launched coverage on Cellebrite DI Ltd. (NASDAQ: CLBT) in its analyst report released on July 19, 2023. The firm assigned the stock a Buy rating. The consensus rating for Cellebrite DI Ltd. (CLBT) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CLBT, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is CLBT’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $12.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Cellebrite DI Ltd. (CLBT) stock is $9.83.
